Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-low Breast Cancer 1Cervical Cancer Recurrent 1Breast Neoplasms 1

Interventions

pyrotinib 2pertuzumab 2Trastuzumab 2disitamab vedotin 1atezolizumab 1RC48 antibody 1Drug Therapy 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2-positive Metastatic Breast Cancer × RC48 antibody × Clear all
NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡